Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Changes in Bone Mass After Discontinuation of Pre-Exposure Prophylaxis (PrEP) with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.

Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K.

Clin Infect Dis. 2019 Jun 8. pii: ciz486. doi: 10.1093/cid/ciz486. [Epub ahead of print]

PMID:
31179503
2.

Improving the Youth HIV Prevention and Care Continuums: The Adolescent Medicine Trials Network for HIV/AIDS Interventions.

Lee S, Kapogiannis BG, Allison S.

JMIR Res Protoc. 2019 Mar 26;8(3):e12050. doi: 10.2196/12050.

3.

Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.

Havens PL, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):123-128. doi: 10.1089/AID.2018.0096. Epub 2018 Nov 5.

PMID:
30280906
4.

Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.

Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.

Antivir Ther. 2018;23(7):623-628. doi: 10.3851/IMP3269. Epub 2018 Sep 27.

PMID:
30260797
5.

Advancing HIV Biomedical Prevention Research for At-Risk Adolescents.

Kapogiannis BG, Nelson RM, Siberry GK, Lee S, Hazra R.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):535-542. doi: 10.1097/QAI.0000000000001853.

PMID:
30204722
6.

Advancing independent adolescent consent for participation in HIV prevention research.

Shah SK, Allison SM, Kapogiannis BG, Black R, Dawson L, Erbelding E.

J Med Ethics. 2018 Jul;44(7):431-433. doi: 10.1136/medethics-2018-104959. Epub 2018 Jun 12. No abstract available.

PMID:
29895555
7.

Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team.

Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753.

8.

HIV Continuum of Care for Youth in the United States.

Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, Fortenberry JD, Monte D, Tanney MR, McFarland EJ, Xu J, Kapogiannis BG, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):110-117. doi: 10.1097/QAI.0000000000001563.

9.

Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.

Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, Fortenberry JD, Hosek SG.

J Adolesc Health. 2017 Dec;61(6):747-754. doi: 10.1016/j.jadohealth.2017.06.013. Epub 2017 Sep 28.

10.

Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents.

Knopf AS, Gilbert AL, Zimet GD, Kapogiannis BG, Hosek SG, Fortenberry JD, Ott MA; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AJOB Empir Bioeth. 2017 Jul-Sep;8(3):145-152. doi: 10.1080/23294515.2016.1251506. Epub 2016 Oct 21.

11.

Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.

Fortenberry JD, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.

JAMA Pediatr. 2017 Jul 1;171(7):687-693. doi: 10.1001/jamapediatrics.2017.0454. Erratum in: JAMA Pediatr. 2017 Jul 1;171(7):712.

12.

Evaluating Testing Strategies for Identifying Youths With HIV Infection and Linking Youths to Biomedical and Other Prevention Services.

Miller RL, Boyer CB, Chiaramonte D, Lindeman P, Chutuape K, Cooper-Walker B, Kapogiannis BG, Wilson CM, Fortenberry JD.

JAMA Pediatr. 2017 Jun 1;171(6):532-537. doi: 10.1001/jamapediatrics.2017.0105.

13.

Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.

Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):241-245. doi: 10.1097/QAI.0000000000001355.

14.

Bridging Knowledge Gaps to Understand How Zika Virus Exposure and Infection Affect Child Development.

Kapogiannis BG, Chakhtoura N, Hazra R, Spong CY.

JAMA Pediatr. 2017 May 1;171(5):478-485. doi: 10.1001/jamapediatrics.2017.0002.

PMID:
28241263
15.

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.

Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.

16.

Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.

Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL; REACH Study and the PACTG 219219C Study.

AIDS. 2016 Mar 27;30(6):889-98. doi: 10.1097/QAD.0000000000001003.

17.

Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.

Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, Patton ED, Ren W, Thornton SE, Major-Wilson HO, Puga AM, Sleasman JW, Rudy BJ, Wilson CM, Garvie PA; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

J Neurovirol. 2016 Apr;22(2):218-30. doi: 10.1007/s13365-015-0389-0. Epub 2015 Oct 13.

18.

Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research.

Gilbert AL, Knopf AS, Fortenberry JD, Hosek SG, Kapogiannis BG, Zimet GD.

J Adolesc Health. 2015 Jul;57(1):113-9. doi: 10.1016/j.jadohealth.2015.03.017.

19.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW; Adolescent Trials Network for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549.

20.

Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.

Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML.

Sex Transm Dis. 2015 May;42(5):246-52. doi: 10.1097/OLQ.0000000000000264.

21.

Evaluation of the effect of human immunodeficiency virus-related structural interventions: the connect to protect project.

Ellen JM, Greenberg L, Willard N, Korelitz J, Kapogiannis BG, Monte D, Boyer CB, Harper GW, Henry-Reid LM, Friedman LB, Gonin R.

JAMA Pediatr. 2015 Mar;169(3):256-63. doi: 10.1001/jamapediatrics.2014.3010.

22.

A comparison of network-based strategies for screening at-risk Hispanic/Latino adolescents and young adults for undiagnosed asymptomatic HIV infection.

Boyer CB, Robles-Schrader GM, Li SX, Miller RL, Korelitz J, Price GN, Rivera Torres CM, Chutuape KS, Stines SJ, Straub DM, Peralta L, Febo I, Hightow-Weidman L, Gonin R, Kapogiannis BG, Ellen JM.

J Adolesc Health. 2014 Dec;55(6):765-73. doi: 10.1016/j.jadohealth.2014.07.009. Epub 2014 Sep 13.

23.

Profiles of Risk Among HIV-Infected Youth in Clinic Settings.

Fernández MI, Huszti HC, Wilson PA, Kahana S, Nichols S, Gonin R, Xu J, Kapogiannis BG.

AIDS Behav. 2015 May;19(5):918-30. doi: 10.1007/s10461-014-0876-y.

24.

Exploration of the Effect of Tobacco Smoking on Metabolic Measures in Young People Living with HIV.

Rubinstein ML, Harris DR, Rudy BJ, Kapogiannis BG, Aldrovandi GM, Mulligan K.

AIDS Res Treat. 2014;2014:740545. doi: 10.1155/2014/740545. Epub 2014 Jul 9.

25.

Evidence-based programming for adolescent HIV prevention and care: operational research to inform best practices.

Kapogiannis BG, Legins KE, Chandan U, Lee S.

J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S228-35. doi: 10.1097/QAI.0000000000000177.

PMID:
24918600
26.

Executive summary: opportunities for action and impact to address HIV and AIDS in adolescents.

Kasedde S, Kapogiannis BG, McClure C, Luo C.

J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S139-43. doi: 10.1097/QAI.0000000000000206.

PMID:
24918589
27.

Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.

Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team.

Antivir Ther. 2014;19(6):613-8. doi: 10.3851/IMP2755. Epub 2014 Feb 17.

28.

Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.

29.

Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.

Nichols SL, Bethel J, Garvie PA, Patton DE, Thornton S, Kapogiannis BG, Ren W, Major-Wilson H, Puga A, Woods SP.

J Adolesc Health. 2013 Dec;53(6):763-71. doi: 10.1016/j.jadohealth.2013.07.006. Epub 2013 Aug 21.

30.

Preventing HIV among young people: research priorities for the future.

Pettifor A, Bekker LG, Hosek S, DiClemente R, Rosenberg M, Bull SS, Allison S, Delany-Moretlwe S, Kapogiannis BG, Cowan F; HIV Prevention Trials Network (HPTN) Adolescent Scientific Committee.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S155-60. doi: 10.1097/QAI.0b013e31829871fb. Review.

31.

Disparities in mental health care among HIV-infected youth.

Whiteley LB, Brown LK, Swenson R, Kapogiannis BG, Harper GW.

J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):29-34. doi: 10.1177/2325957413488172. Epub 2013 May 21.

32.

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.

Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.

Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10.

33.

Comprehension of a simplified assent form in a vaccine trial for adolescents.

Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SE, Hoffman D, Wilson CM, Cunningham CK; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

J Med Ethics. 2013 Jun;39(6):410-2. doi: 10.1136/medethics-2012-101286. Epub 2013 Jan 24.

34.

An assessment of the feasibility and acceptability of a friendship-based social network recruitment strategy to screen at-risk African American and Hispanic/Latina young women for HIV infection.

Boyer CB, Hightow-Weidman L, Bethel J, Li SX, Henry-Reid L, Futterman D, Maturo D, Straub DM, Howell K, Reid S, Lowe J, Kapogiannis BG, Ellen JM.

JAMA Pediatr. 2013 Mar 1;167(3):289-96. doi: 10.1001/2013.jamapediatrics.398.

35.

Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure?

Pace JE, Siberry GK, Hazra R, Kapogiannis BG.

Clin Infect Dis. 2013 Apr;56(8):1149-55. doi: 10.1093/cid/cis1020. Epub 2012 Dec 7.

36.

Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.

Syed SS, Balluz RS, Kabagambe EK, Meyer WA 3rd, Lukas S, Wilson CM, Kapogiannis BG, Nachman SA, Sleasman JW.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):493-500. doi: 10.1089/AID.2012.0086. Epub 2012 Dec 3.

37.

Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.

Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

J Clin Endocrinol Metab. 2012 Nov;97(11):4004-13. doi: 10.1210/jc.2012-2600. Epub 2012 Aug 29.

38.

Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9. doi: 10.1097/QAI.0b013e3182676fe3.

39.

Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.

Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM; ATN 021 Protocol team.

Clin Infect Dis. 2012 Aug;55(3):461-8. doi: 10.1093/cid/cis455. Epub 2012 May 9.

40.

Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.

Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG; ATN 061 Team and the Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AIDS Patient Care STDS. 2012 Apr;26(4):193-6. No abstract available.

41.

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team.

Clin Infect Dis. 2012 Apr;54(7):1013-25. doi: 10.1093/cid/cir968. Epub 2012 Jan 19.

42.

Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).

Kapogiannis BG, Soe MM, Nesheim SR, Abrams EJ, Carter RJ, Farley J, Palumbo P, Koenig LJ, Bulterys M.

Clin Infect Dis. 2011 Nov;53(10):1024-34. doi: 10.1093/cid/cir641.

43.

Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.

Rudy BJ, Kapogiannis BG, Lally MA, Gray GE, Bekker LG, Krogstad P, McGowan I.

J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S31-42. doi: 10.1097/QAI.0b013e3181e3a922.

44.

Introduction: Paving the way for biomedical HIV prevention interventions in youth.

Kapogiannis BG, Handelsman E, Ruiz MS, Lee S.

J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S1-4. doi: 10.1097/QAI.0b013e3181e2cf8f.

PMID:
20571417
45.

Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.

Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K; Adolescent Trials Network for HIV/AIDS Interventions.

Vaccine. 2010 May 7;28(21):3672-8. doi: 10.1016/j.vaccine.2010.03.022. Epub 2010 Mar 28.

46.

Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.

Cunningham CK, Rudy BJ, Xu J, Bethel J, Kapogiannis BG, Ahmad S, Wilson CM, Flynn PM; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

Pediatr Infect Dis J. 2010 Jun;29(6):530-4. doi: 10.1097/INF.0b013e3181d285c7.

47.

Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.

Mulligan K, Harris DR, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA 3rd, Sleasman J, Wilson CM, Aldrovandi GM; Adolescent Trials Network 021 Protocol Team.

Clin Infect Dis. 2010 Jan 1;50(1):106-14. doi: 10.1086/648728.

48.

Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.

Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM, Tang J.

Hum Genet. 2009 Nov;126(5):685-96. doi: 10.1007/s00439-009-0720-z. Epub 2009 Jul 14.

49.

Creative and tailored strategies needed to foster researcher-community partnerships.

Chutuape K, Willard N, Kapogiannis BG, Ellen JM.

Am J Public Health. 2009 Mar;99(3):390. doi: 10.2105/AJPH.2008.151993. Epub 2008 Dec 23. No abstract available.

50.

Adolescents in clinical trials.

Kapogiannis BG, Mattison DR.

Clin Pharmacol Ther. 2008 Dec;84(6):655-9. doi: 10.1038/clpt.2008.191. Erratum in: Clin Pharmacol Ther. 2009 Feb;85(2):222.

PMID:
19008903

Supplemental Content

Loading ...
Support Center